Israel Englander Chimerix Inc Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Chimerix Inc stock. As of the latest transaction made, Millennium Management LLC holds 2,557,530 shares of CMRX stock, worth $12.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,557,530

Previous 2,395,735 6.75%

Holding current value

$12.2 Million

Previous $2.23 Million 299.46%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.83 - $3.48 $134,289 - $563,046	161,795 Added 6.75%	2,557,530 $8.9 Million
Q3 2024 Nov 14, 2024	BUY	$0.77 - $1.07 $1.06 Million - $1.47 Million	1,374,430 Added 134.58%	2,395,735 $2.23 Million
Q2 2024 Aug 14, 2024	SELL	$0.87 - $1.05 $60,578 - $73,111	-69,630 Reduced 6.38%	1,021,305 $898,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.26 $3,032 - $4,198	3,332 Added 0.31%	1,090,935 $1.16 Million
Q4 2023 Feb 14, 2024	SELL	$0.9 - $1.06 $1.1 Million - $1.29 Million	-1,220,439 Reduced 52.88%	1,087,603 $1.04 Million
Q2 2023 Aug 14, 2023	BUY	$1.1 - $1.54 $1.39 Million - $1.94 Million	1,260,884 Added 120.41%	2,308,042 $2.79 Million
Q1 2023 May 15, 2023	SELL	$1.19 - $2.09 $286,554 - $503,276	-240,802 Reduced 18.7%	1,047,158 $1.32 Million
Q4 2022 Feb 14, 2023	SELL	$1.67 - $2.35 $4.5 Million - $6.33 Million	-2,691,954 Reduced 67.64%	1,287,960 $2.4 Million
Q3 2022 Nov 14, 2022	BUY	$1.81 - $2.76 $6.81 Million - $10.4 Million	3,762,185 Added 1727.92%	3,979,914 $7.68 Million
Q2 2022 Aug 15, 2022	SELL	$1.34 - $5.34 $11,879 - $47,339	-8,865 Reduced 3.91%	217,729 $453,000
Q1 2022 May 16, 2022	SELL	$4.58 - $6.8 $266,020 - $394,964	-58,083 Reduced 20.4%	226,594 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $960,311 - $1.32 Million	-183,616 Reduced 39.21%	284,677 $1.83 Million
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $629,247 - $926,922	-105,934 Reduced 18.45%	468,293 $2.9 Million
Q2 2021 Aug 16, 2021	BUY	$7.54 - $9.79 $3.56 Million - $4.63 Million	472,789 Added 466.09%	574,227 $4.59 Million
Q1 2021 May 17, 2021	BUY	$4.76 - $11.25 $325,584 - $769,500	68,400 Added 207.03%	101,438 $978,000
Q4 2020 Feb 16, 2021	SELL	$2.43 - $5.42 $457,853 - $1.02 Million	-188,417 Reduced 85.08%	33,038 $160,000
Q3 2020 Nov 16, 2020	SELL	$2.3 - $3.72 $307,493 - $497,337	-133,693 Reduced 37.64%	221,455 $551,000
Q2 2020 Aug 14, 2020	BUY	$1.33 - $3.63 $238,289 - $650,368	179,165 Added 101.81%	355,148 $1.1 Million
Q1 2020 May 14, 2020	SELL	$1.27 - $2.33 $391,393 - $718,068	-308,184 Reduced 63.65%	175,983 $253,000
Q4 2019 Feb 14, 2020	BUY	$1.3 - $2.72 $240,700 - $503,618	185,154 Added 61.92%	484,167 $983,000
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $1.01 Million - $2.2 Million	-522,559 Reduced 63.6%	299,013 $702,000
Q2 2019 Aug 15, 2019	BUY	$2.05 - $4.32 $996,094 - $2.1 Million	485,900 Added 144.75%	821,572 $3.55 Million
Q2 2019 Aug 14, 2019	BUY	$2.05 - $4.32 $520,029 - $1.1 Million	253,673 Added 309.36%	335,672 $23.8 Million
Q1 2019 May 14, 2019	SELL	$1.79 - $3.12 $436,135 - $760,191	-243,651 Reduced 74.82%	81,999 $172,000
Q4 2018 Feb 14, 2019	BUY	$2.24 - $3.9 $147,871 - $257,454	66,014 Added 25.43%	325,650 $837,000
Q3 2018 Nov 14, 2018	SELL	$3.58 - $4.9 $89,457 - $122,441	-24,988 Reduced 8.78%	259,636 $1.01 Million
Q2 2018 Aug 14, 2018	BUY	$4.43 - $5.14 $137,733 - $159,807	31,091 Added 12.26%	284,624 $1.36 Million
Q1 2018 May 15, 2018	BUY	$4.65 - $5.9 $820,766 - $1.04 Million	176,509 Added 229.16%	253,533 $1.32 Million
Q4 2017 Feb 14, 2018	BUY	$4.32 - $5.52 $117,054 - $149,569	27,096 Added 54.27%	77,024 $357,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.25 $217,186 - $262,122	49,928	49,928 $262,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

40.3M

Call Options Held

243K

Put Options Held

110K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $417M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account